phaeochromocytoma and paraganglioma

in review 4 min read Updated 2026-11-19
phaeochromocytoma and paraganglioma

Screen with plasma free metanephrines (drawn supine) or 24-h urine fractionated metanephrines — never VMA. Image only after biochemical confirmation (CT first per ES 2014; MRI for skull base/neck, pregnancy, or metastatic disease). Every functional tumour requires 7–14 days of α-blockade plus high-sodium diet and fluids before surgery; add a β-blocker only after adequate α-blockade. Engage all patients in genetic testing (30–40% hereditary) and arrange lifelong annual metanephrines.


who to test

  • Classic triad (episodic headache, diaphoresis, palpitations) or spells with pallor/anxiety
  • Paroxysmal, labile, or severe refractory hypertension (see also secondary hypertension)
  • Paradoxical hypertensive surge triggered by β-blockers, metoclopramide, glucocorticoids, MAOIs, TCAs, induction of anaesthesia, surgery, or micturition (bladder paraganglioma)
  • adrenal incidentaloma that is >10 HU or heterogeneous on unenhanced CT (not required if homogeneous ≤10 HU per ESE 2023)
  • Hereditary predisposition or family history (MEN2, VHL, NF1, SDHx) or prior PPGL

biochemical diagnosis (ES 2014)

  • First-line tests (equivalent sensitivity ~96–99%): plasma free metanephrines or 24-h urinary fractionated metanephrines (measured by LC-MS/MS or LC-ECD)
    • HTN Canada 2020 lists 24-h urine first with plasma free metanephrines where available; never use urinary VMA
  • Pre-analytical rigour: draw plasma free metanephrines supine (after ≥20–30 min rest) and compare against supine reference ranges (seated sampling causes high false-positive rates)
  • Interpreting results:
    • ≥3–4× ULN (or elevation of both metanephrine and normetanephrine): high specificity → proceed directly to localising imaging
    • Borderline (1–3× ULN): review interfering drugs and acute physiologic stress, repeat supine; if persistently equivocal, perform a clonidine suppression test (lack of ≥40% normetanephrine suppression at 3 h supports PPGL)
  • Common false positives: TCAs, SNRIs, MAOIs, sympathomimetics/decongestants, phenoxybenzamine, L-dopa, antipsychotics/metoclopramide, acute critical illness, OSA, and acetaminophen (on LC-ECD assays)

imaging and genetics

localisation (only after biochemical confirmation)

  • CT abdomen/pelvis (and thorax if abdominal CT negative): first-choice modality per ES 2014 due to spatial resolution (HTN Canada 2020 prefers MRI; note adrenal phaeos are typically >10 HU on unenhanced CT)
  • MRI preferred for: skull base/neck paragangliomas, metastatic PPGL, pregnancy, children, contrast allergy, or surgical clip artefact
  • Functional imaging: ¹⁸F-FDG PET/CT is preferred over ¹²³I-MIBG for metastatic disease; reserve ¹²³I-MIBG for metastatic disease when considering ¹³¹I-MIBG targeted radiotherapy (also ⁶⁸Ga-DOTATATE PET/CT in specialised centres for SDHx/paraganglioma)

genetic testing (ES 2014)

  • Up to 30–40% of PPGLs carry a germline mutation — engage all patients in shared decision-making for genetic counselling and testing via an accredited laboratory
  • Prioritise paraganglioma for SDHx testing and metastatic PPGL for SDHB (highest metastatic risk, ~30–50%)
syndrome / genecatecholamine profilekey clinical associations
MEN2A / MEN2B (RET)epinephrine (metanephrine) dominantmedullary thyroid cancer, PHPT (2A), marfanoid habitus / mucosal neuromas (2B)
VHL (VHL)norepinephrine (normetanephrine) dominantretinal/CNS haemangioblastomas, clear-cell RCC, pancreatic cysts/NETs
NF1 (NF1)mixed / epinephrinecafé-au-lait macules, neurofibromas, Lisch nodules, axillary freckling
Hereditary PGL (SDHB, SDHD, SDHC, SDHA)norepinephrine / dopamineextra-adrenal/head-and-neck paragangliomas; SDHB carries high metastatic risk

perioperative medical blockade and surgery

never start a β-blocker before α-blockade

Blocking vasodilatory β₂-receptors leaves α₁-vasoconstriction unopposed and can trigger a hypertensive crisis, pulmonary oedema, or cardiogenic shock. Labetalol has fixed ~1:5 α:β activity and can also cause paradoxical hypertension — never use it as initial therapy.

preoperative preparation (ES 2014 / HTN Canada 2020)

  • Mandatory for all hormonally functional PPGLs: start α-adrenergic blockade 7–14 days pre-op (HTN Canada: 10–14 days) to normalise BP and HR
    • Non-selective: phenoxybenzamine (classic; longer post-op hypotension, reflex tachycardia)
    • Selective α₁-blockers: doxazosin, prazosin, or terazosin (less reflex tachycardia and post-op hypotension; widely used in Canada)
    • Calcium channel blockers (e.g., amlodipine, nifedipine) are useful adjuncts if BP remains elevated or if α-blockade is poorly tolerated
  • Volume expansion: high-sodium diet and liberal fluid intake (starting a few days after α-blockade begins) to reverse chronic catecholamine-induced intravascular volume contraction and prevent severe post-resection hypotension; avoid diuretics
  • β-blocker: add only after adequate α-blockade is established, solely to control reflex tachycardia (e.g., propranolol, metoprolol, atenolol)
  • Target pre-op: seated BP <130/80 mmHg, standing SBP >90 mmHg, HR 60–80 bpm

surgery and post-operative surveillance

  • Surgical approach: laparoscopic adrenalectomy for most adrenal phaeochromocytomas; open resection for large (>6 cm) or invasive phaeochromocytomas and most paragangliomas to prevent tumour rupture; consider cortex-sparing partial adrenalectomy in hereditary bilateral disease (VHL, MEN2)
  • Immediate post-op monitoring (ES 2014, strong): monitor BP, HR, and blood glucose closely for 24–48 h — abrupt withdrawal of catecholamines causes post-resection hypotension (treat with IV fluids ± vasopressors) and rebound hypoglycaemia (loss of α₂-mediated insulin suppression)
  • Long-term follow-up: measure plasma or urine metanephrines post-operatively to confirm complete resection, then perform lifelong annual biochemical testing to detect recurrence or late metastasis

Prepared 2026-11-19. Not yet verified — check every number against the sources.

Key references

+2 more sources

Suggest a correction phaeochromocytoma and paraganglioma